How Retatrutide Works
Frequently asked questions about retatrutide's mechanism of action, including its triple receptor agonism and how it differs from other metabolic therapies.
What does 'triple agonist' mean?
A triple agonist is a single molecule that activates three different receptor types. Retatrutide activates GIP receptors, GLP-1 receptors, and glucagon receptors. Each receptor triggers different biological effects, and their simultaneous activation produces complementary metabolic benefits that are hypothesized to be greater than any single receptor pathway alone.
What does GLP-1 receptor activation do?
GLP-1 receptor activation reduces appetite through effects on brain satiety centers, stimulates insulin secretion in a glucose-dependent manner (lowering blood sugar without causing dangerous drops), suppresses glucagon release from the pancreas, and slows gastric emptying. This is the same mechanism used by approved drugs like semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda).
What does GIP receptor activation do?
GIP receptor activation enhances insulin secretion, influences adipose (fat) tissue function, and may contribute to appetite suppression through brain pathways. When combined with GLP-1 receptor activation, GIP appears to amplify the metabolic benefits, as demonstrated by tirzepatide (Mounjaro/Zepbound), which targets both GIP and GLP-1 receptors.
What does glucagon receptor activation do?
Glucagon receptor activation increases energy expenditure (the number of calories the body burns at rest) and promotes fatty acid oxidation in the liver (burning stored fat for energy). This component is unique to retatrutide among advanced clinical candidates and is thought to explain the enhanced weight loss and dramatic liver fat reduction observed in clinical trials.
Why doesn't the glucagon component raise blood sugar?
Glucagon naturally raises blood glucose by stimulating the liver to release stored sugar. In retatrutide, this glucose-raising effect is counterbalanced by the simultaneous GLP-1 and GIP receptor activation, which promote insulin secretion and suppress excessive glucagon signaling. Clinical trial data confirm that the net effect is improved, not worsened, blood sugar control.
Why is retatrutide given once weekly?
Retatrutide's peptide structure includes a fatty acid modification that allows it to bind to albumin, a protein in the blood. This albumin binding protects the drug from being broken down quickly and extends its half-life to approximately six days, meaning that a single injection provides sustained drug levels throughout a full week.
How does retatrutide cause weight loss?
Retatrutide promotes weight loss through two complementary mechanisms: reducing caloric intake (through appetite suppression mediated by GLP-1 and GIP receptor activation in the brain) and increasing caloric expenditure (through energy expenditure increases driven by glucagon receptor activation). This dual approach to the energy balance equation distinguishes it from single- and dual-agonist therapies that primarily reduce intake.